glp-1 receptor agonist antipsychotic weight gain study Impacts of Glucagon-like Peptide-1 Receptor-Agonist (GLP-1 RA) Treatment for Metabolic Disturbances and in Patients on Clozapine/Olanzapine: A Systematic Review Comparative effects of pharmacological treatment
Description
Exenatide, released in 2005 as Byetta, is the oldest GLP analog
The addition of lixisenatide to standard therapy did not significantly alter the rates of CV events or hospitalizations in high-risk patients, although it did result in modest but significant reductions in A1c, weight, and systolic BP compared to standard therapy
Other novel and very well known protein and pathways are emerging as promising longevity targets
visualisation, R.L
